Health Care Company Coherus BioSciences Announces Merger With Surface Oncology
Portfolio Pulse from Benzinga Insights
Coherus BioSciences (NASDAQ:CHRS) has announced a merger with Surface Oncology (NASDAQ:SURF) expected to be completed in Q3 of 2023. Coherus BioSciences will give Surface Oncology $40 million in exchange for SURF stock, with the payment method yet to be disclosed.
June 16, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences announces merger with Surface Oncology, expected to complete in Q3 2023. The company will give $40 million in exchange for SURF stock.
The merger announcement is directly related to Coherus BioSciences and is expected to have a positive short-term impact on the stock price. Mergers typically lead to increased investor interest and potential synergies between the companies involved.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Surface Oncology announces merger with Coherus BioSciences, expected to complete in Q3 2023. The company will receive $40 million in exchange for its stock.
The merger announcement is directly related to Surface Oncology and is expected to have a positive short-term impact on the stock price. Mergers typically lead to increased investor interest and potential synergies between the companies involved.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100